Taken together, these aspects support an immunotherapeutic approach for pediatric medulloblastoma patients carrying the EPC2–GULP1 fusion and possibly other gene fusions and could contribute to an immunogenicity-based stratification of medulloblastoma. This evidence concerns the gene EPC2 and medulloblastoma.